NO20044592L - Aryl keton pyrrolo-triazinforbindelser nyttige som kinase inhibitorer - Google Patents

Aryl keton pyrrolo-triazinforbindelser nyttige som kinase inhibitorer

Info

Publication number: NO20044592L
Authority: NO; Norway
Prior art keywords: kinase inhibitors; compounds useful; aryl ketone; pyrrolotriazine compounds; pyrrolotriazine
Prior art date: 2002-04-23

Application number

NO20044592A

Other languages

English (en)

Norwegian (no)

Inventor

Katerina Leftheris

John Hynes

Alaric Dyckman

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-23

Filing date

2004-10-25

Publication date

2004-11-19

2004-10-25 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2004-11-19 Publication of NO20044592L publication Critical patent/NO20044592L/no

Links

229940043355 kinase inhibitor Drugs 0.000 title abstract 2
239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
-1 Aryl ketone pyrrolotriazine compounds Chemical class 0.000 title 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical group 0.000 abstract 1
150000002431 hydrogen Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Endocrinology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Transplantation (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20044592A 2002-04-23 2004-10-25 Aryl keton pyrrolo-triazinforbindelser nyttige som kinase inhibitorer NO20044592L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US37490702P	2002-04-23	2002-04-23
PCT/US2003/012420 WO2003091229A1 (en)	2002-04-23	2003-04-18	Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors

Publications (1)

Publication Number	Publication Date
NO20044592L true NO20044592L (no)	2004-11-19

Family

ID=29270567

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20044592A NO20044592L (no)	2002-04-23	2004-10-25	Aryl keton pyrrolo-triazinforbindelser nyttige som kinase inhibitorer

Country Status (14)

Country	Link
US (1)	US7314876B2 (is)
EP (1)	EP1503996B1 (is)
JP (1)	JP2005529890A (is)
AR (1)	AR039648A1 (is)
AT (1)	ATE418546T1 (is)
AU (1)	AU2003221753A1 (is)
DE (1)	DE60325469D1 (is)
ES (1)	ES2318122T3 (is)
IS (1)	IS7504A (is)
NO (1)	NO20044592L (is)
PE (1)	PE20040411A1 (is)
PL (1)	PL373371A1 (is)
TW (1)	TW200306841A (is)
WO (1)	WO2003091229A1 (is)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6867300B2 (en)	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en) *	2000-11-17	2003-12-30	Bristol-Myers Squibb Company	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) *	2001-11-14	2003-06-01	Bristol Myers Squibb Co	C-5 modified indazolylpyrrolotriazines
US7388009B2 (en)	2002-04-23	2008-06-17	Bristol-Myers Squibb Company	Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
PT1497019E (pt)	2002-04-23	2015-09-10	Bristol Myers Squibb Co	Compostos de pirrolotriazina anilina úteis como inibidores de quinase
TW200306841A (en)	2002-04-23	2003-12-01	Bristol Myers Squibb Co	Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
TW200400034A (en)	2002-05-20	2004-01-01	Bristol Myers Squibb Co	Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TW200401638A (en) *	2002-06-20	2004-02-01	Bristol Myers Squibb Co	Heterocyclic inhibitors of kinases
TWI329112B (en) *	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
AU2003265349A1 (en) *	2002-08-02	2004-02-23	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
TW200420565A (en) *	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines
ATE552236T1 (de)	2003-01-14	2012-04-15	Cytokinetics Inc	Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz
JP2006516653A (ja)	2003-02-05	2006-07-06	ブリストル−マイヤーズ　スクイブ　カンパニー	キナーゼ阻害剤ピロロトリアジンの製造方法
US20060014741A1 (en) *	2003-12-12	2006-01-19	Dimarco John D	Synthetic process, and crystalline forms of a pyrrolotriazine compound
US7102001B2 (en) *	2003-12-12	2006-09-05	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine
MY145634A (en) *	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
US7064203B2 (en)	2003-12-29	2006-06-20	Bristol Myers Squibb Company	Di-substituted pyrrolotriazine compounds
US7652146B2 (en)	2004-02-06	2010-01-26	Bristol-Myers Squibb Company	Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
US7459562B2 (en) *	2004-04-23	2008-12-02	Bristol-Myers Squibb Company	Monocyclic heterocycles as kinase inhibitors
TW200538453A (en)	2004-04-26	2005-12-01	Bristol Myers Squibb Co	Bicyclic heterocycles as kinase inhibitors
US7102002B2 (en)	2004-06-16	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
ES2522579T3 (es)	2004-06-17	2014-11-17	Cytokinetics, Inc.	Compuestos, composiciones y métodos
US7432373B2 (en)	2004-06-28	2008-10-07	Bristol-Meyers Squibb Company	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en)	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
US7173031B2 (en)	2004-06-28	2007-02-06	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7253167B2 (en) *	2004-06-30	2007-08-07	Bristol-Myers Squibb Company	Tricyclic-heteroaryl compounds useful as kinase inhibitors
TW200600513A (en)	2004-06-30	2006-01-01	Bristol Myers Squibb Co	A method for preparing pyrrolotriazine compounds
US7102003B2 (en) *	2004-07-01	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
US7176222B2 (en)	2004-07-27	2007-02-13	Cytokinetics, Inc.	Syntheses of ureas
US7504521B2 (en)	2004-08-05	2009-03-17	Bristol-Myers Squibb Co.	Methods for the preparation of pyrrolotriazine compounds
TW200618803A (en)	2004-08-12	2006-06-16	Bristol Myers Squibb Co	Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
US7151176B2 (en) *	2004-10-21	2006-12-19	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
TW200635927A (en) *	2004-12-22	2006-10-16	Bristol Myers Squibb Co	Synthetic process
US7534882B2 (en)	2005-04-06	2009-05-19	Bristol-Myers Squibb Company	Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles
US7538223B2 (en)	2005-08-04	2009-05-26	Cytokinetics, Inc.	Compounds, compositions and methods
US7880004B2 (en)	2005-09-15	2011-02-01	Bristol-Myers Squibb Company	Met kinase inhibitors
US7547782B2 (en)	2005-09-30	2009-06-16	Bristol-Myers Squibb Company	Met kinase inhibitors
US7514435B2 (en) *	2005-11-18	2009-04-07	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7348325B2 (en)	2005-11-30	2008-03-25	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
ES2419007T3 (es)	2005-12-15	2013-08-19	Cytokinetics, Inc.	Ciertas entidades químicas, composiciones y procedimientos
US7825120B2 (en)	2005-12-15	2010-11-02	Cytokinetics, Inc.	Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
WO2007078815A2 (en)	2005-12-16	2007-07-12	Cytokinetics, Inc.	Certain chemical entities, compositions, and methods
WO2007078839A2 (en)	2005-12-19	2007-07-12	Cytokinetics, Inc.	Compounds, compositions and methods
US8063208B2 (en) *	2006-02-16	2011-11-22	Bristol-Myers Squibb Company	Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
KR20080107408A (ko)	2006-03-07	2008-12-10	브리스톨-마이어스 스큅 컴퍼니	키나제 억제제로서 유용한 피롤로트리아진 아닐린 전구약물화합물
ES2539620T3 (es)	2008-12-19	2015-07-02	Cephalon, Inc.	Pirrolotriazina como inhibidor de ALK y de JAK2
WO2012031057A1 (en)	2010-09-01	2012-03-08	Bristol-Myers Squibb Company	Bms- 582949 for the treatment of resistant rheumatic disease
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
BR112020006677A2 (pt)	2017-10-05	2020-10-06	Fulcrum Therapeutics, Inc.	uso de inibidores p38 para reduzir a expressão de dux4
US20240132521A1 (en)	2022-08-22	2024-04-25	Iambic Therapeutics, Inc.	Compounds and methods for modulating her2

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6147080A (en)	1996-12-18	2000-11-14	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
US6251914B1 (en)	1997-07-02	2001-06-26	Smithkline Beecham Corporation	Cycloalkyl substituted imidazoles
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
ATE232205T1 (de)	1998-10-01	2003-02-15	Astrazeneca Ab	Chinolin- und chinazolin derivate und ihre verwendung als inhibitoren von krankheiten, bei denen cytokine beteiligt wird
GB9906566D0 (en)	1999-03-23	1999-05-19	Zeneca Ltd	Chemical compounds
JP4649046B2 (ja) *	1999-05-21	2011-03-09	ブリストル−マイヤーズスクイブカンパニー	キナーゼのピロロトリアジン阻害剤
US6787545B1 (en)	1999-08-23	2004-09-07	Shiongi & Co., Ltd.	Pyrrolotriazine derivatives having spla2-inhibitory activities
GB9924092D0 (en)	1999-10-13	1999-12-15	Zeneca Ltd	Pyrimidine derivatives
ES2237470T3 (es)	1999-11-10	2005-08-01	Ortho-Mcneil Pharmaceutical, Inc.	2-aril-3-(heteroaril)-imidazo(1,2-alfa)pirimidinas sustituidas; y composiciones farmaceuticas y procedimientos asociados.
US20020065270A1 (en)	1999-12-28	2002-05-30	Moriarty Kevin Joseph	N-heterocyclic inhibitors of TNF-alpha expression
US6906067B2 (en)	1999-12-28	2005-06-14	Bristol-Myers Squibb Company	N-heterocyclic inhibitors of TNF-α expression
GEP20063915B (en)	2000-11-17	2006-09-11	Bristol Myers Squibb Co	PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
US6867300B2 (en)	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en) *	2000-11-17	2003-12-30	Bristol-Myers Squibb Company	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
AU2002316421B2 (en)	2001-06-26	2008-05-15	Bristol-Myers Squibb Company	N-heterocyclic inhibitors of TNF-ALPHA expression
TW200300350A (en)	2001-11-14	2003-06-01	Bristol Myers Squibb Co	C-5 modified indazolylpyrrolotriazines
TW200306841A (en)	2002-04-23	2003-12-01	Bristol Myers Squibb Co	Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
TW200400034A (en)	2002-05-20	2004-01-01	Bristol Myers Squibb Co	Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TWI329112B (en)	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
TWI272271B (en)	2002-07-19	2007-02-01	Bristol Myers Squibb Co	Process for preparing certain pyrrolotriazine compounds
AU2003265349A1 (en)	2002-08-02	2004-02-23	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
TW200420565A (en)	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines

2003
- 2003-04-18 TW TW092109124A patent/TW200306841A/zh unknown
- 2003-04-18 ES ES03718493T patent/ES2318122T3/es not_active Expired - Lifetime
- 2003-04-18 PL PL03373371A patent/PL373371A1/xx not_active Application Discontinuation
- 2003-04-18 EP EP03718493A patent/EP1503996B1/en not_active Expired - Lifetime
- 2003-04-18 AT AT03718493T patent/ATE418546T1/de not_active IP Right Cessation
- 2003-04-18 JP JP2003587789A patent/JP2005529890A/ja not_active Withdrawn
- 2003-04-18 WO PCT/US2003/012420 patent/WO2003091229A1/en not_active Ceased
- 2003-04-18 DE DE60325469T patent/DE60325469D1/de not_active Expired - Lifetime
- 2003-04-18 AU AU2003221753A patent/AU2003221753A1/en not_active Abandoned
- 2003-04-22 US US10/420,445 patent/US7314876B2/en not_active Expired - Lifetime
- 2003-04-23 PE PE2003000401A patent/PE20040411A1/es not_active Application Discontinuation
- 2003-04-23 AR ARP030101400A patent/AR039648A1/es unknown
2004
- 2004-10-14 IS IS7504A patent/IS7504A/is unknown
- 2004-10-25 NO NO20044592A patent/NO20044592L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PL373371A1 (en)	2005-08-22
EP1503996B1 (en)	2008-12-24
PE20040411A1 (es)	2004-07-14
IS7504A (is)	2004-10-14
US7314876B2 (en)	2008-01-01
US20030232831A1 (en)	2003-12-18
JP2005529890A (ja)	2005-10-06
ATE418546T1 (de)	2009-01-15
AU2003221753A1 (en)	2003-11-10
ES2318122T3 (es)	2009-05-01
EP1503996A4 (en)	2006-05-17
DE60325469D1 (de)	2009-02-05
EP1503996A1 (en)	2005-02-09
TW200306841A (en)	2003-12-01
WO2003091229A1 (en)	2003-11-06
AR039648A1 (es)	2005-03-02

Legal Events

Date	Code	Title	Description
2008-11-24	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20044592L (no)	2004-11-19	Aryl keton pyrrolo-triazinforbindelser nyttige som kinase inhibitorer
GEP20063915B (en)	2006-09-11	PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
NO20025821L (no)	2003-02-04	2-aminokarbonyl-9H-purinderivater
NO20044974L (no)	2004-11-16	Imidazo [1,2-a]pyrazin-8-ylaminer, fremgangsmater for fremstilling og anvendelse derav
NO20044866L (no)	2004-12-17	Pyrazolo-pyrimidin-anilin-forbindelser anvendelige som kinase-inhibitorer
MY132094A (en)	2007-09-28	Pyrrolo-triazine aniline compounds useful as kinase inhibitors
NO20021328L (no)	2002-05-21	Pyrazolopyrimidier som terapeutiske midler
PL377285A1 (pl)	2006-01-23	Podstawione pochodne pirolo-pirazolowe jako inhibitory kinazy
GB0124933D0 (en)	2001-12-05	Chemical compounds
NO20066055L (no)	2007-01-24	Pyridinderivater
SE0202463D0 (sv)	2002-08-14	Novel compounds
NO20072399L (no)	2007-08-24	Nye pyrrolo[3,2-d]pyrimidin-4-o-derivater og deres anvendelse i terapi
BR0212760A (pt)	2004-12-07	Compostos quìmicos
NO20063231L (no)	2006-07-11	Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
WO2006084017A3 (en)	2006-12-14	Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
DK1412354T3 (da)	2006-09-18	Derivater af triazolylimidazopyridin og af triazolylpurinerne, der er egnede som ligander for adenosin A2a?-receptoren og deres anvendelse som medikamenter
NO20033145L (no)	2003-09-09	Purinderivater som purinergiske reseptorantagonister
DE602004012758D1 (de)	2008-05-08	Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung
NO20015172L (no)	2002-01-23	1-metyl-erytromycin-derivater
MXPA03009750A (es)	2004-06-30	Compuestos quimicos.
GB0308201D0 (en)	2003-05-14	Novel compounds
WO2003082861A3 (en)	2004-03-11	Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases
MXPA04000407A (es)	2004-03-18	Derivados de fenilacetamido-tiazol, procedimiento para su preparacion y uso como agentes antitumorales.
NO20060146L (no)	2006-03-07	Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20050666L (no)	2005-03-11	2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer